AKT1 and prostate carcinoma: In accordance with the Akt signalling pathway being an important regulator of NED [123], miR-17, -20b, and -106b negatively regulated AKT3, whose expression accompanied the NED phenotype in clinical samples of advanced prostate cancer [313].